Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Kidney Neoplasms × PT2385 × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Kidney Neoplasms 1 Carcinoma, Renal Cell 1

Interventions

pembrolizumab 11 Nivolumab 7 Cyclophosphamide 6 aldesleukin 5 Sunitinib 5 Sorafenib 5 Everolimus 5 temsirolimus 4 belzutifan 4 Ipilimumab 4 fludarabine 3 cabozantinib 3 atezolizumab 3 Interferon-alpha 3 Gene Expression Profiling 3 Fluorouracil 3 Docetaxel 3 Busulfan 3 sargramostim 2 perifosine 2 pazopanib 2 ixabepilone 2 entinostat 2 ciforadenant 2 belinostat 2 Thiotepa 2 Temozolomide 2 Sirolimus 2 Reverse Transcriptase Polymerase Chain Reaction 2 Radiotherapy 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02293980 2024-06-17

MK-3795-001

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 1 Active not recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡